New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 2, 2014
08:13 EDTSTJSt. Jude Medical resolves FDA warning letter for Sylmar facility
St. Jude Medical announced that it has been notified by the U.S. Food and Drug Administration that issues cited in the Sylmar, California facility’s warning letter have been addressed. The company said, “We take our responsibility as a medical device manufacturer very seriously. We are encouraged by the resolution of the FDA’s warning letter and will continue to work to ensure the highest standards are met across our manufacturing facilities. St. Jude Medical is committed to providing our patients, customers and regulators with products and services that meet or exceed their expectations of safety, high-quality performance, reliability and service.”
News For STJ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 4, 2015
09:14 EDTSTJSt. Jude Medical closes acquisition of Spinal Modulation
Subscribe for More Information
07:23 EDTSTJAmerican Association of Neurological Surgeons to hold annual meeting
Subscribe for More Information
April 30, 2015
09:07 EDTSTJSt. Jude Medical receives FDA approval for Protege MRI system
Subscribe for More Information
April 23, 2015
10:00 EDTSTJOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:05 EDTSTJSt. Jude Medical price target raised to $85 from $77 at Leerink
Subscribe for More Information
06:40 EDTSTJSt. Jude Medical upgraded to Outperform from Neutral at Credit Suisse
Subscribe for More Information
April 22, 2015
08:49 EDTSTJSt. Jude Medical sees FY16 a 'strong year' for neuromodulation segment
Subscribe for More Information
08:30 EDTSTJSt. Jude Medical sees FY15 CRM constant currency sales down 2% to flat with FY14
Sees FY15 AF product sales growth of 12%-14%. Backs cardiovascular product sales growth view of 6%-8%. Sees neuromodulation products sales growth 13%-15%. Sees acquisition of spinal modulation reducing FY15 EPS by about 5c and accretive to FY16 EPS. Guidance provided during Q1 earnings conference call.
07:18 EDTSTJSt. Jude Medical sees Q2 adjusted EPS 99c-$1.01, consensus 99c
For the second quarter, St. Jude Medical expects revenue to grow in the range of 4%-5% on a constant currency basis compared to the second quarter of 2014 with currency negatively impacting second quarter revenue by approximately $125M-$135M. Revenue consensus is $1.4B.
07:18 EDTSTJSt. Jude Medical sees FY15 adjusted EPS $3.92-$3.97, consensus $3.95
Subscribe for More Information
07:16 EDTSTJSt. Jude Medical reports Q1 total CRM sales $643M, down 6% y/y
Subscribe for More Information
07:16 EDTSTJSt. Jude Medical reports Q1 adjusted EPS 93c, consensus 91c
Reports Q1 revenue $1.35B, consensus $1.32B.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use